Literature DB >> 11912113

Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy.

Dominique Caparros-Lefebvre1, Nicolas Sergeant, Andrew Lees, Agnes Camuzat, Susan Daniel, Annie Lannuzel, Alexis Brice, Eduardo Tolosa, Andre Delacourte, Charles Duyckaerts.   

Abstract

An unusually high frequency of atypical Parkinson syndrome has been delineated over the last 5 years in the French West Indies. Postural instability with early falls, prominent frontal lobe dysfunction and pseudo-bulbar palsy were common and three-quarters of the patients were L-dopa unresponsive. One-third of all patients seen had probable progressive supranuclear palsy (PSP). This new focus of atypical parkinsonism is reminiscent of the one described in Guam and may be linked to exposure to tropical plants containing mitochondrial complex I inhibitors (quinolines, acetogenins, rotenoids). Two hundred and twenty consecutive patients with Parkinson's syndrome seen by the neurology service at Pointe à Pitre, Guadeloupe University Hospital were studied. Currently accepted operational clinical criteria for Parkinson's syndromes were applied. The pathological findings of three patients who came to autopsy are reported. Fifty-eight patients had probable PSP, 96 had undetermined parkinsonism and 50 had Parkinson's disease, 15 had amyotrophic lateral sclerosis with parkinsonism and one had probable multiple system atrophy. All three PSP patients in whom post-mortem study was performed had early postural instability, gaze palsy and parkinsonian symptoms, followed by a frontolimbic dementia and corticobulbar signs. Neuropathological examination showed an accumulation of tau proteins, predominating in the midbrain. There was an exceptionally large accumulation of neuropil threads in Case 1. Biochemical studies detected a major doublet of pathological tau at 64 and 69 kDa in brain tissue homogenates. All cases were homozygous for the H1 tau haplotype, but no mutation of the tau gene was observed. Clinical, neuropathological and biochemical features were compatible with the diagnosis of PSP, although some unusual pathological features were noted in Case 1. A cluster of cases presenting with atypical parkinsonism is reported. Guadeloupean parkinsonism may prove to be a tauopathy identical or closely related to PSP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11912113     DOI: 10.1093/brain/awf086

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  20 in total

Review 1.  Vertical supranuclear gaze palsy in Niemann-Pick type C disease.

Authors:  Ettore Salsano; Chizoba Umeh; Alessandra Rufa; Davide Pareyson; David S Zee
Journal:  Neurol Sci       Date:  2012-07-19       Impact factor: 3.307

2.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  A geographical cluster of progressive supranuclear palsy in northern France.

Authors:  Dominique Caparros-Lefebvre; Lawrence I Golbe; Vincent Deramecourt; Claude-Alain Maurage; Vincent Huin; Valerie Buée-Scherrer; Helene Obriot; Bernard Sablonnière; Francois Caparros; Luc Buée; Andrew J Lees
Journal:  Neurology       Date:  2015-09-09       Impact factor: 9.910

Review 4.  Tauopathies as clinicopathological entities.

Authors:  David J Irwin
Journal:  Parkinsonism Relat Disord       Date:  2015-09-08       Impact factor: 4.891

Review 5.  Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?

Authors:  Christopher A Shaw; Günter U Höglinger
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

6.  REM sleep behavior disorder in patients with guadeloupean parkinsonism, a tauopathy.

Authors:  Valérie Cochen De Cock; Annie Lannuzel; Stéphane Verhaeghe; Emmanuel Roze; Merle Ruberg; Jean Philippe Derenne; Jean Claude Willer; Marie Vidailhet; Isabelle Arnulf
Journal:  Sleep       Date:  2007-08       Impact factor: 5.849

Review 7.  Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.

Authors:  A C Ludolph; J Kassubek; B G Landwehrmeyer; E Mandelkow; E-M Mandelkow; D J Burn; D Caparros-Lefebvre; K A Frey; J G de Yebenes; T Gasser; P Heutink; G Höglinger; Z Jamrozik; K A Jellinger; A Kazantsev; H Kretzschmar; A E Lang; I Litvan; J J Lucas; P L McGeer; S Melquist; W Oertel; M Otto; D Paviour; T Reum; A Saint-Raymond; J C Steele; M Tolnay; H Tumani; J C van Swieten; M T Vanier; J-P Vonsattel; S Wagner; Z K Wszolek
Journal:  Eur J Neurol       Date:  2009-03       Impact factor: 6.089

Review 8.  Update on progressive supranuclear palsy.

Authors:  Irene Litvan
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

9.  Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons.

Authors:  Myriam Escobar-Khondiker; Matthias Höllerhage; Marie-Paule Muriel; Pierre Champy; Antoine Bach; Christel Depienne; Gesine Respondek; Elizabeth S Yamada; Annie Lannuzel; Takao Yagi; Etienne C Hirsch; Wolfgang H Oertel; Ralf Jacob; Patrick P Michel; Merle Ruberg; Günter U Höglinger
Journal:  J Neurosci       Date:  2007-07-18       Impact factor: 6.167

Review 10.  Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants.

Authors:  G Lopez; K Bayulkem; M Hallett
Journal:  Acta Neurol Scand       Date:  2016-01-06       Impact factor: 3.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.